Axsome Therapeutics Inc
AXSM103.160USD
+0.140+0.14%
Horário de mercado （ET）Cotações atrasadas em 15 min
5.08BValor de mercado
PerdaP/L TTM
Mais detalhes de Axsome Therapeutics Inc Empresa
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Informações da empresa
Código da empresaAXSM
Nome da EmpresaAxsome Therapeutics Inc
Data de listagemNov 19, 2015
CEODr. Herriot Tabuteau, M.D.
Número de funcionários683
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 19
EndereçoOne World Trade Center, 29Th Floor
CidadeNEW YORK
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal10007
Telefone12123323241
Sitehttps://www.axsome.com/
Código da empresaAXSM
Data de listagemNov 19, 2015
CEODr. Herriot Tabuteau, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
167.67K
--
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
5.78K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Coleman, M.D.
Dr. Mark Coleman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Ari Maizel
Mr. Ari Maizel
Chief Commercial Officer
Chief Commercial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
167.67K
--
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
5.78K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q4
FY2023Q3
Por EmpresaUSD
Nome
Receita
Proporção
Auvelitv
96.23M
79.23%
Sunosi
24.13M
19.86%
Sunosi royality revenue
1.10M
0.91%
Por RegiãoUSD
Nome
Receita
Proporção
United States
119.41M
98.31%
Outside of the United States
2.05M
1.69%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Auvelitv
96.23M
79.23%
Sunosi
24.13M
19.86%
Sunosi royality revenue
1.10M
0.91%
Distribuição de ações
Atualizado em: sáb, 12 de jul
Atualizado em: sáb, 12 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Antecip Capital, L.L.C.
14.92%
The Vanguard Group, Inc.
7.86%
BlackRock Institutional Trust Company, N.A.
6.03%
RTW Investments L.P.
5.94%
BVF Partners L.P.
3.43%
Other
61.82%
Investidores
Investidores
Proporção
Antecip Capital, L.L.C.
14.92%
The Vanguard Group, Inc.
7.86%
BlackRock Institutional Trust Company, N.A.
6.03%
RTW Investments L.P.
5.94%
BVF Partners L.P.
3.43%
Other
61.82%
Tipos de investidores
Investidores
Proporção
Investment Advisor
33.54%
Investment Advisor/Hedge Fund
22.21%
Corporation
14.92%
Hedge Fund
14.24%
Research Firm
2.73%
Private Equity
1.51%
Individual Investor
1.39%
Pension Fund
1.17%
Sovereign Wealth Fund
0.82%
Other
7.48%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
614
46.10M
93.63%
-4.69M
2025Q1
613
46.35M
94.71%
-3.83M
2024Q4
570
46.09M
94.52%
-5.46M
2024Q3
540
47.31M
97.60%
-6.48M
2024Q2
526
49.58M
103.45%
-2.44M
2024Q1
512
47.53M
101.57%
-4.95M
2023Q4
484
47.45M
101.62%
-3.96M
2023Q3
475
47.05M
100.91%
-2.63M
2023Q2
475
45.53M
98.82%
+628.64K
2023Q1
467
40.73M
95.65%
-3.70M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Antecip Capital, L.L.C.
7.34M
14.92%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
3.87M
7.86%
-26.20K
-0.67%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.97M
6.03%
-40.30K
-1.34%
Mar 31, 2025
RTW Investments L.P.
2.92M
5.94%
-1.13M
-27.86%
Mar 31, 2025
BVF Partners L.P.
1.69M
3.43%
+302.16K
+21.77%
Mar 31, 2025
Macquarie Investment Management
976.26K
1.98%
+12.21K
+1.27%
Mar 31, 2025
Geode Capital Management, L.L.C.
934.85K
1.9%
+22.32K
+2.45%
Mar 31, 2025
Fidelity Management & Research Company LLC
916.73K
1.86%
+275.45K
+42.95%
Mar 31, 2025
State Street Global Advisors (US)
906.02K
1.84%
-41.23K
-4.35%
Mar 31, 2025
Fairmount Funds Management LLC
815.18K
1.66%
-653.81K
-44.51%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
SPDR S&P Pharmaceuticals ETF
3.7%
ALPS Medical Breakthroughs ETF
3.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.62%
Tema Neuroscience and Mental Health ETF
2.52%
iShares U.S. Pharmaceuticals ETF
2.17%
Virtus LifeSci Biotech Products ETF
1.89%
First Trust Mid Cap Growth AlphaDEX Fund
0.6%
iShares Health Innovation Active ETF
0.59%
Invesco Nasdaq Biotechnology ETF
0.57%
ProShares Ultra Nasdaq Biotechnology
0.57%
Ver Mais
SPDR S&P Pharmaceuticals ETF
Proporção3.7%
ALPS Medical Breakthroughs ETF
Proporção3.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção2.62%
Tema Neuroscience and Mental Health ETF
Proporção2.52%
iShares U.S. Pharmaceuticals ETF
Proporção2.17%
Virtus LifeSci Biotech Products ETF
Proporção1.89%
First Trust Mid Cap Growth AlphaDEX Fund
Proporção0.6%
iShares Health Innovation Active ETF
Proporção0.59%
Invesco Nasdaq Biotechnology ETF
Proporção0.57%
ProShares Ultra Nasdaq Biotechnology
Proporção0.57%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
